Literature DB >> 26926816

Common Questions About Chronic Prostatitis.

James D Holt1, W Allan Garrett1, Tyler K McCurry1, Joel M H Teichman2.   

Abstract

Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bacterial prostatitis (CBP), chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS), and asymptomatic inflammatory prostatitis. CBP and CNP/CPPS both lead to pelvic pain and lower urinary tract symptoms. CBP presents as recurrent urinary tract infections with the same organism identified on repeated cultures; it responds to a prolonged course of an antibiotic that adequately penetrates the prostate, if the urine culture suggests sensitivity. If four to six weeks of antibiotic therapy is effective but symptoms recur, another course may be prescribed, perhaps in combination with alpha blockers or nonopioid analgesics. CNP/CPPS, accounting for more than 90% of chronic prostatitis cases, presents as prostatic pain lasting at least three months without consistent culture results. Weak evidence supports the use of alpha blockers, pain medications, and a four- to six-week course of antibiotics for the treatment of CNP/CPPS. Patients may also be referred to a psychologist experienced in managing chronic pain. Experts on this condition recommend a combination of treatments tailored to the patient's phenotypic presentation. Urology referral should be considered when appropriate treatment is ineffective. Additional treatments include pelvic floor physical therapy, phytotherapy, and pain management techniques. The UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, tenderness) approach summarizes the various factors that may contribute to presentation and can guide treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26926816

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

1.  Genetic and Environmental Influences on Urinary Conditions in Men: A Classical Twin Study.

Authors:  Marianna Gasperi; John N Krieger; Matthew S Panizzon; Jack Goldberg; Dedra Buchwald; Niloofar Afari
Journal:  Urology       Date:  2019-04-13       Impact factor: 2.649

2.  Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis.

Authors:  Nainesh Parikh; Edward Keshishian; Ayushman Sharma; Monica Roca; Brandon Manley; Michael Poch; G Daniel Grass; Javier Torres-Roca; David Boulware; Peter Johnstone; Michael Montejo; Johnna Smith; Julio Pow-Sang; Kosj Yamoah
Journal:  Adv Radiat Oncol       Date:  2020-04-14

3.  The effect of Qianliekang tablets on the clinical efficacy, immune function, and inflammatory factor levels in the prostatic fluid of elderly chronic prostatitis patients.

Authors:  Chao Yang; Jun Yao; Tianping Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Chronic prostatitis and comorbid non-urological overlapping pain conditions: A co-twin control study.

Authors:  Marianna Gasperi; John N Krieger; Christopher Forsberg; Jack Goldberg; Dedra Buchwald; Niloofar Afari
Journal:  J Psychosom Res       Date:  2017-09-06       Impact factor: 3.006

5.  Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway.

Authors:  Yan Zhou; Jun-Hao Wang; Jian-Peng Han; Jian-Yong Feng; Kuo Guo; Fei Du; Wen-Bin Chen; Yong-Zhang Li
Journal:  Inflamm Res       Date:  2022-03-13       Impact factor: 4.575

6.  Efficacy and safety of moxibustion in patients with chronic prostatitis/chronic pelvic pain syndrome: A systematic review protocol.

Authors:  Qianan Cao; Xu Zhou; Jianrong Chen; Yuting Zhong; Haifeng Zhang; Qi Ao; Meilu Liu; Heyun Nie; Weifeng Zhu; Yong Fu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Registered Drug Packs of Antimicrobials and Treatment Guidelines for Prostatitis: Are They in Accordance?

Authors:  Ivan Jerkovic; Ana Seselja Perisin; Josipa Bukic; Dario Leskur; Josko Bozic; Darko Modun; Jonatan Vukovic; Doris Rusic
Journal:  Healthcare (Basel)       Date:  2022-06-22

Review 8.  Therapeutic Applications of Functional Nanomaterials for Prostatitis.

Authors:  Chun-Ping Liu; Zi-De Chen; Zi-Yan Ye; Dong-Yue He; Yue Dang; Zhe-Wei Li; Lei Wang; Miao Ren; Zhi-Jin Fan; Hong-Xing Liu
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

9.  MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing.

Authors:  Li Zhang; Yi Liu; Xian-Guo Chen; Yong Zhang; Jing Chen; Zong-Yao Hao; Song Fan; Li-Gang Zhang; He-Xi Du; Chao-Zhao Liang
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

10.  Dihydroartemisinin Promoted Bone Marrow Mesenchymal Stem Cell Homing and Suppressed Inflammation and Oxidative Stress against Prostate Injury in Chronic Bacterial Prostatitis Mice Model.

Authors:  Shen Li; Yongzhang Li; Xiaozhe Su; Aiyun Han; Yang Cui; Shuyue Lv; Jin Zhang; Chao Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-15       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.